Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Abemaciclib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Abemaciclib as a study intervention. Browse Abemaciclib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
188
Shown on this page
12
Current sort
Recently updated
Therapy scope
Abemaciclib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Abemaciclib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 61–72 of 188 matching trials for Abemaciclib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

NCT03706365
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abemaciclib, Placebo, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 9:09 PM EDT
Recruiting Phase 2 Interventional

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

NCT05999994
View directory record Official record
Conditions
Neoplasms, Child, Adolescent
Interventions
Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel, Abemaciclib, Irinotecan, Temozolomide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 39 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 9:09 PM EDT
Recruiting Phase 1 Interventional

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic NUT Carcinoma, Unresectable Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable NUT Carcinoma
Interventions
Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 9:09 PM EDT
Recruiting Phase 2 Interventional

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

NCT04040205
View directory record Official record
Conditions
Chondrosarcoma, Osteosarcoma, Soft Tissue Sarcoma
Interventions
Abemaciclib
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
4
States / cities
Jacksonville, Florida • Iowa City, Iowa • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 23, 2026, 9:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

NCT05113537
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Metastatic Castration-resistant Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions
Abemaciclib, Lutetium Lu 177-PSMA-617
Drug
Lead sponsor
Vadim S Koshkin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 9:09 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
48
States / cities
Chandler, Arizona • Gilbert, Arizona • Greenbrae, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 9:09 PM EDT
Recruiting Phase 2 Interventional

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

NCT04469764
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Abemaciclib, Anastrozole, Letrozole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 9:09 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

NCT06413706
View directory record Official record
Conditions
Glioma
Interventions
Abemaciclib, Temozolomide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
0 Years to 20 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Orange, California • Palo Alto, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 9:09 PM EDT
Recruiting Phase 2 Interventional

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

NCT07209449
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Abemaciclib, Elacestrant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 9:09 PM EDT
Active, not recruiting Phase 2 Interventional

Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors

NCT03220646
View directory record Official record
Conditions
Brain Tumor
Interventions
abemaciclib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
8
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 23, 2026, 9:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 9:09 PM EDT
Recruiting Phase 4 Interventional

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

NCT06169371
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
3
States / cities
Chicago, Illinois • Iowa City, Iowa • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 9:09 PM EDT

About this Abemaciclib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Abemaciclib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Abemaciclib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Abemaciclib.